Prostatype Genomics AB (publ) (PROGEN.ST) Research

Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.

Market snapshot

Symbol
PROGEN.ST
Price
$0.64
Day change
+28.40%
Market cap
$21.2M
P/E ratio
-0.10x
52-week range
0.28-2.28
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • 2cureX AB (publ) (2CUREX.ST)
  • Aino Health AB (publ) (AINO.ST)
  • Aptahem AB (publ) (APTA.ST)
  • Chordate Medical Holding AB (publ) (CMH.ST)
  • Episurf Medical AB (publ) (EPIS-B.ST)
  • Fluicell AB (publ) (FLUI.ST)
  • ODI Pharma AB (ODI.ST)
  • Qlife Holding AB (publ) (QLIFE.ST)

Open Prostatype Genomics AB (publ) (PROGEN.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.